Lead Compounds for Diagnosis and Therapy of Alzheimer's Disease
UC San Diego researchers have identified several classes of molecules with excellent potential as lead compounds for therapeutic and imaging agents. Their proprietary approach has identified molecules that cannot be identified using historic methods. These compounds include non-dye classes of therapeutics and diagnostics for Alzheimer's disease and may provide alternatives to radiolabeled PET imaging agents and molecules under clinical development. By obviating the need for specific fluorescent, spectroscopic, radioactive, and mechanistic properties, this approach is yielding classes of compounds more compatible with and readily translatable to clinical practice. Specifically, many of these proprietary compounds have: Low molecular weight. Known and favorable pharmacokinetic properties. Known permeability across the blood-brain barrier. Ready commercial availability. FDA approval as drugs. Finally, while this approach has been developed using beta-amyloid fibrils found in Alzheimer's disease, the same high-throughput screen may be adapted to identify therapeutic/diagnostic agents for other neurologic diseases, including Parkinson's, Huntington, Down's Syndrome, bovine spongiform encephalopathy (mad cow disease), Kuru, Creutzfeldt-Jakob disease, and fatal familial insomnia.
Patent Number: US7666886B2
Application Number: US2006487224A
Inventor: Yang, Jerry | Inbar, Petra
Priority Date: 15 Jul 2005
Priority Number: US7666886B2
Application Date: 14 Jul 2006
Publication Date: 23 Feb 2010
IPC Current: A01N004378 | A61K0031425 | C07D027760 | C07D027762
US Class: 514367 | 548152
Assignee Applicant: The Regents of the University of California
Title: Compounds and methods for the diagnosis and treatment of amyloid associated diseases
Usefulness: Compounds and methods for the diagnosis and treatment of amyloid associated diseases
Summary: For diagnosing, preventing or alleviating the symptoms of an amyloid associated disease e.g. neuronal disease such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Down's Syndrome, and spongiform encephalopathy (claimed). For screening for a compound that blocks the binding of an A-β fibril binding molecule to A-β fibrils, screening for a compound used for diagnostic imaging of A-β-fibrils; diagnosing an amyloid associated disease in an individual, identifying a change in the progress of an amyloid associated disease in an individual and detecting amyloid deposits in an individual e.g. mammal such as human (all claimed). For diagnosing imaging of A-β fibrils and for studying normal or disease-associated cellular mechanism relating to amyloid proteins. The research reagent are used to detect the presence of an amyloid-associated disease or to assist in screening for compounds that may prevent or alleviate the symptoms of the disease, for inhibition of the interaction of an amyloid protein with a second binding protein to enable the study of a cellular or disease mechanism.
Novelty: New phenylbenzothiazoles useful for diagnosing and treating or preventing an amyloid associated disease e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease
Biomedical
Medical Composition
7666886
Related Materials Intellectual Property Info See issued patents Additional Technologies by these Inventors Tech ID/UC Case 19515/2006-105-0 Related Cases 2006-105-0, 2007-018-2, 2007-056-1
USA
